Details:
The Proceeds from the financing will be used to advance the Company’s lead program ProGly-Uricase into the clinic for the treatment of refractory gout and to broaden the GRObio pipeline.
Lead Product(s): Undisclosed
Therapeutic Area: Rheumatology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Atlas Venture
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 19, 2024